Skip to main content
. 2019 Mar 12;105(9):1256–1262. doi: 10.1136/bjophthalmol-2018-312767

Figure 2.

Figure 2

Sustained remission and relapse during follow up. Kaplan Meier estimator curve of the probability ofpatients (y-axis) experiencing (A) sustained remission and (B) relapse following remission on eitheradalimumab or infliximab. The x-axis shows the time to either outcome.